Pub. Date:
Springer Berlin Heidelberg
Antitumor Antibiotics / Edition 1

Antitumor Antibiotics / Edition 1


Current price is , Original price is $139.99. You

Temporarily Out of Stock Online

Please check back later for updated availability.


The scientific collaboration between the United States and Japan in the field of cancer goes back many years. In this successful international collaboration cancer chemotherapy has been one of the most productive areas. Pioneers such as YOSHIDA, UMEZAWA, SHEAR, and GOLDIN established firm links of mutual trust and respect in the period after the Second Great War. Japanese drugs, such as mitomycin C and bleomycin have become mainstays of clinical oncology in the U. S. and throughout the world. Many drugs developed in the U. S. have become established in Japanese cancer therapy. Within the cancer chemotherapy field the antitumor antibiotics rank as one of the most important groups. In the U . S. -J apanese collaboration this group of drugs has taken the paramount role. The Japanese, under the leadership of U mezawa, are considered to be among the most innovative and productive in this area which has also had great emphasis in the United States as part of the National Cancer Institute's drug development program and in the pharmaceutical industry. This extended collaboration in general oncology, and chemotherapy in particular, has received increased impetus by and support from the official U . S. -J apan Joint Agreement on cancer research, which was established in 1974 between the National Cancer Institute and the Japanese Society for the Promotion of Science. One of the subsections of this agreement is cancer therapy with emphasis on chemotherapy.

Product Details

ISBN-13: 9783642812217
Publisher: Springer Berlin Heidelberg
Publication date: 12/15/2011
Series: Recent Results in Cancer Research , #63
Edition description: Softcover reprint of the original 1st ed. 1978
Pages: 303
Product dimensions: 6.69(w) x 9.61(h) x 0.03(d)

Table of Contents

1. Summary of Clinical Data on Antitumor Antibiotics in Japan.- 2. Role of Antitumor Antibiotics in Current Oncologic Practice.- 3. Historical Overview of the National Cancer Institute Fermentation Program.- 4. National Cancer Institute’s Fermentation Development Program.- 5. In Vivo Antitumor Evaluation of Antibiotics. Selected Results from the Drug Evaluation Program of the National Cancer Institute, U.S.A..- 6. Antitumor Antibiotic Bioactivation, Biotransformation, and Derivatization by Microbial Systems.- 7. Detection and Assay of Antitumor Antibiotics.- 8. Fingerprint Methods Used to Identify Known Antineoplastic Agents in Culture Filtrates.- 9. Microbial Process Translation—Laboratory to Pilot Plant at the Frederick Cancer Research Center.- 10. Criteria for Selection of New Analogs of Antitumor Antibiotics.- 11. Preclinical Status of Macromomycin at the National Cancer Institute.- 12. New Microbial Secondary Metabolites Under Preclinical Development for Cancer Treatment.- 13. The Current Status of Chemotherapy for Gastric Cancer in Japan with Special Emphasis on Mitomycin C.- 14. Mitomycin C: Experience in the United States, With Emphasis on Gastric Cancer.- 15. A Review of the Bleomycin Experience in the United States.- 16. Combined Use of Bleomycin with Radiation in the Treatment of Cancer.- 17. A Sequential Combination of Bleomycin and Mitomycin C in the Treatment of Advanced Squamous Cancers.- 18. Fundamental and Clinical Studies on New Bleomycin Analogs.- 19. Experimental Results with the Combination of Bleomycin Plus Mitomycin C.- 20. Studies on the Clinical Pharmacology of Bleomycin.- 21. Adriamycin and Other Anthracycline Antibiotics Under Study in the United States.- 22. Clinical Experiences With Aclacinomycin—A.- 23. Clinical Aspects of Adriamycin in Japan.- 24. Clinical Investigations of Neocarzinostatin in Japan.- 25. Neocarzinostatin: Initial Clinical and Pharmacologic Studies in the United States.- 26. Synthetic Analogs of Antitumor Drugs Under Development in Japan.- 27. New Anticancer Antibiotics Under Development and Clinical Evaluation in the National Cancer Institute.- 28. Clinical Evaluation of New Antitumor Antibiotics.- 29. Antitumor Antibiotics—Thoughts for the Future.

Customer Reviews